Skip to Content

Zimhi FDA Approval Status

Last updated by Judith Stewart, BPharm on May 20, 2020.

FDA Approved: No
Brand name: Zimhi
Generic name: naloxone hydrochloride
Dosage form: Injection
Company: Adamis Pharmaceuticals Corporation
Treatment for: Opioid Overdose

Zimhi (naloxone hydrochloride) is a high-dose formulation of the approved opioid antagonist naloxone in development for the treatment of opioid overdose.

Development Timeline for Zimhi

DateArticle
Jun  9, 2021Adamis Provides Update on Zimhi
May 17, 2021Adamis Pharmaceuticals Resubmits Zimhi New Drug Application to FDA for the Treatment of Opioid Overdose
Nov 16, 2020Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding Zimhi
May 20, 2020Adamis Pharmaceuticals Resubmits Zimhi New Drug Application to FDA

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.